[PDF] Cochlear-Internal Canal and Cochlear-Facial Dehiscence: A Novel Entity
O Garaycochea, PD Domínguez, M Manrique… - 2018
… facial dehiscence. CASE PRESENTATION A 53-year-old patient with the diagnosis
of a refractory bilateral Meniere's disease was referred to our center. He … vertigo spells.
Clinical symptoms suggested Meniere's disease. However …
of a refractory bilateral Meniere's disease was referred to our center. He … vertigo spells.
Clinical symptoms suggested Meniere's disease. However …
 |  |  |
[PDF] Probable Benign Paroxysmal Positional Vertigo Converts into Definite BPPV in One in Six Patients
H van der Zaag-Loonen, T Bruintjes, R van Leeuwen - Hypertension, 2018
… participate. Possible risk factors for BPPV, such as (head) trauma in the past,
hypertension, migraine, Meniere's disease, diabetes, osteoporosis, and a
cerebrovascular attack in the past, were extracted from the medical records [7] …
hypertension, migraine, Meniere's disease, diabetes, osteoporosis, and a
cerebrovascular attack in the past, were extracted from the medical records [7] …
| | |
A Revisit to High Jugular Bulb: A Newer Clinical Grading
KC Prasad, CH Basava, PN Gopinathan, G Induvarsha… - Indian Journal of …, 2018
… High jugular bulb may also mimic Meniere's disease showing severe acute
ver- tiginous attacks, pulsatile tinnitus, and hearing loss [6]. If suspected
preoperatively, investigation with CT angiography or venography may provide …
ver- tiginous attacks, pulsatile tinnitus, and hearing loss [6]. If suspected
preoperatively, investigation with CT angiography or venography may provide …
| | |
Managing Patients With Acute Episodic Dizziness
JA Edlow - Annals of Emergency Medicine, 2018
Skip to Main Content …
| | |
FORMULATIONS OF N-ACETYLCYSTEINE AND USES THEREOF
RE Gammans - US Patent App. 15/874,285, 2018
… 21. A method of treating acute acoustic trauma, sensory neural hearing loss,
tinnitus, vertigo, Meniere's disease, aminoglycoside, carboplatin, or cisplatin
induced hearing loss, endolympahtic hydrops, stroke, or renal or hepatic …
tinnitus, vertigo, Meniere's disease, aminoglycoside, carboplatin, or cisplatin
induced hearing loss, endolympahtic hydrops, stroke, or renal or hepatic …
| | |
[PDF] Collateral Damage: An Overview of Hearing Loss and Listening Disorders in Pediatric Cancer Treatment
AR Ehrlich - 2018
… Far less common is low-frequency hearing loss which is generally reported in individuals
with Meniere's disease. Hearing loss is categorized as a low-frequency, notch, or high
frequency loss de- pending on the range of frequencies most affected …
with Meniere's disease. Hearing loss is categorized as a low-frequency, notch, or high
frequency loss de- pending on the range of frequencies most affected …
| | |
A Comprehensive Study of Oxidative Stress in Tinnitus Patients
M Celik, İ Koyuncu - Indian Journal of Otolaryngology and Head & Neck …, 2018
… The harmful effects of oxidative stress are well known in some inner ear
diseases such as Meniere's disease, impulsive induced hearing loss, drug
ototoxicity, labyrinthitis [21, 22]. The lipid peroxidation produced by ROS …
diseases such as Meniere's disease, impulsive induced hearing loss, drug
ototoxicity, labyrinthitis [21, 22]. The lipid peroxidation produced by ROS …
| | |
Otosclerosis
S Mansour, J Magnan, K Nicolas, H Haidar - Middle Ear Diseases, 2018
… Occasionally, dizziness may be the expression of an associated pathology like
Meniere's disease … Paparella and Chasin reported about otosclerosis patients with
typical signs and symptoms of Meniere's disease [72]. Shea et al …
Meniere's disease … Paparella and Chasin reported about otosclerosis patients with
typical signs and symptoms of Meniere's disease [72]. Shea et al …
| | |
ANTIBODY MOLECULES WHICH BIND CD79
HM Finney, SE Rapecki, KL Tyson, MJ Wright - US Patent App. 15/743,764, 2018
The present disclosure relates to antibody molecules comprising a binding
domain specific to CD79, said binding domain comprising SEQ ID NO: 1,
2, 3 or 4, and/or SEQ ID NO: 5, 6 and 7. The disclosure.
domain specific to CD79, said binding domain comprising SEQ ID NO: 1,
2, 3 or 4, and/or SEQ ID NO: 5, 6 and 7. The disclosure.
| | |
BINDING POLYPEPTIDES AND METHODS OF MAKING THE SAME
Z Shriver, G Babcock, L Robinson - US Patent App. 15/852,718, 2018
Polypeptides, such as antibody molecules and TCR molecules, and
methods of making the same, are disclosed. The polypeptides can
be used to treat, prevent, and/or diagnose disorders.
methods of making the same, are disclosed. The polypeptides can
be used to treat, prevent, and/or diagnose disorders.
| | |
Αυτή η ειδοποίηση αποστέλλεται από τον Μελετητή Google. Ο Μελετητής Google είναι μια υπηρεσία που παρέχεται από την Google.
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου